Yan Hong-Mei, et al.
PloS one, 2015
Abstract
Objectives
A randomized, parallel controlled, open-label clinical trial was conducted to evaluate the effect of a botanic compound berberine (BBR) on NAFLD.
Methods
A randomized, parallel controlled, open-label clinical trial was conducted in three medical centers (NIH Registration number: NCT00633282). A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0.5g tid, respectively, for 16 weeks. Hepatic fat content (HFC), serum glucose and lipid profiles, liver enzymes and serum and urine BBR concentrations were assessed before and after treatment. We also analyzed hepatic BBR content and expression of genes related to glucose and lipid metabolism in an animal model of NAFLD treated with BBR.
Results
As compared with LSI, BBR treatment plus LSI resulted in a significant reduction of HFC (52.7% vs 36.4%, p = 0.008), paralleled with better improvement in body weight, HOMA-IR, and serum lipid profiles (all p<0.05). BBR was more effective than PGZ 15mg qd in reducing body weight and improving lipid profile. BBR-related adverse events were mild and mainly occurred in digestive system. Serum and urine BBR concentrations were 6.99ng/ml and 79.2ng/ml, respectively, in the BBR-treated subjects. Animal experiments showed that BBR located favorably in the liver and altered hepatic metabolism-related gene expression.
Conclusion
BBR ameliorates NAFLD and related metabolic disorders. The therapeutic effect of BBR on NAFLD may involve a direct regulation of hepatic lipid metabolism.
Trial registration
ClinicalTrials.gov NCT00633282.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.| PMID: | 26252777 |
|---|---|
| PMCID (Free PMC Article): | PMC4529214 |
| DOI: | 10.1371/journal.pone.0134172 |
| Category: | Healthy Liver Support |
The best supplements with Berberine in Healthy Liver Support category:
- Detoxyn - Most of the human population are carriers of at least one parasite. It contains among others: Berberine.
Articles similar to "Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease."
- The significance of Berberine for Healthy Liver Support: Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. ( Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic manifestation of metabolic syndrome... BBR improved NAFLD by inhibiting glucogenesis and comprehensively regulating lipid metabolism, and its effect on inhibiting hepatic lipogenesis was much stronger. The improvement may be partly mediated by weight loss. Berberine might be a good choice for patients with NAFLD and glucose metabolic disorder. Future clinical trials need to be conducted to confirm these effects. )
Previous article
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Next article
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.